Dr. Shiu @NHS NEOPRISM-CRC high-risk stII-III CRC #MSI -H neoadj pembro X1 then if high TMB 2 more cycles of pembro (33 of 34 pts had TMB high) ➡️ 59% pCR rate (primary endpoint), 2 G>3 irAEs, few surgical complications

#ASCO24 OncoAlert

🎥Giannis Mountzios of Henry Dunant highlights challenges in selecting 2nd-line treatments for advanced #NSCLC after chemo-IO

Key factors include:
👉Timing of progression,
👉Patient characteristics
👉NGS data

ow.ly/mnza50S5VEf

ASCO #ASCO24 #LungCancer #LCSM OncoAlert

Our Friends/Collaborators at VJ Oncology got you covered after #ASCO24 with GU highlights from their experts on all the great science out of Chicago.

Tune in for GU Cancer Highlights
20th of June, 5pm CEST
us06web.zoom.us/webinar/regist…

Here the safety data of #DESTINYbreast06 : we should keep to be vigilant on risk of interstitial lung disease with use of trastuzumab-deruxtecan #TDXd

#ASCO24 OncoAlert G Curigliano MD PhD

#ASCO24 ASCO

Such important messages to start Day3️⃣.

So many centers including ours now offering this in 🇺🇸 and globally🌎.

@oncoalert

👏🏼👏🏼👏🏼 Matthew Goetz I applaud you for your question at the #DB06 session #ASCO24

I echo what you said!

All patients should have got it regardless of #HER2_low #HER2_Ultra_Low or #HER2_IHC_0 status and then check if response differs between those 3 groups!

OncoAlert VJ Oncology

Do patients with ER-low (1-10%) tumors benefit from adjuvant ET⁉️
At #ASCO24 an analysis of >10,000 ER-low tumors shows that ET omission was associated with ⬇️ overall survival, suggesting that adjuvant ET should be recommended to these patients as standard of care
OncoAlert

CB101 soto+carbo/pem cohort. 1stline ORR 65% l, mPFS 10.8mo. mPFS 11.9mo in PDL1neg. 8.3mo mPFS 2L+. TRAEs mostly heme. V low rates of G3+ ALT rise if IO non-exposed.

>>v encouraging efficacy with low AE rate. Ongoing CB202 ph3 trial testing this further

#ASCO24

‼️
Ivonescimab (PD-1/VEGF) + chemo post Osimertinib

✅ ⬆️ PFS
❓ ⬆️ OS benefit (immature)
✅ ⬆️ ORR
✅ ⬆️ DoR
✅ Minor additional tox vs. chemo

🤔 Impressive PFS benefit: same as MARIPOSA-2
🤔 None of Amivantamab toxicity issues
🤔 Big challenge to Ami 🤜🤜

#ASCO24 #LCSM

G Curigliano MD PhD masterfully presents a paradigm shifting #DB06 at #ASCO24

Two shifts here in practice:

1️⃣ With an addntl 20-25% being 'ultra low' (<10% but some staining), we now have around 85% clearly appropriate for TDXd (5 mo improvement)

2️⃣now 1st L after ET for ER+ #bcsm

When you have a full #ASCO24 room at 7 am, you know it will be a pretty relevant session. #DB06 G Curigliano MD PhD

One of the most awaited LBA at #ASCO24
G Curigliano MD PhD presents results of DestinyBreast06 on T-DXd in HR+, HER2-low and -ultralow BC

➡️ T-DXd⬆️PFS vs. TPC in HER2-low mBC

➡️Results in ultra-low consistent with HER2-low

➡️ILD remains an important safety risk

OncoAlert

Cowabunga! Riding Breast Cancer's Biggest Data’s Wave 🏄🏻‍♂️🌊🤙🏻from #ASCO24

DESTINY-B06 🚨ULTRA RESULTS🚨

PFS: 13.2 vs 8.1 m HR 0.62
Ultralow cohort? The same results (13.2 vs 8.1)

No doubt, T-DXd is a NEW story!

OncoAlert Oncology Brothers VJ Oncology OncLive.com ASCO @Oncoinfo

It was great to speak with Tom Powles (@QMBCI) yesterday who discussed KEYNOTE-361 integrating ctDNA monitoring into routine clinical practice for advanced #UC , and highlights from #ASCO24

ASCO #BladderCancer #GUsm #UrothelialCarcinoma OncoAlert

📢As Day 3 of #ASCO24 begins, we’re ready to speak to leading experts on cutting-edge developments in #Oncology !

👀Keep an eye out for our for exclusive ASCO 2024 coverage at VJOncology.com

Dr. Crabb University of Southampton MANCAN2 RCT of self-help cognitive behavioral therapy (CBT) 4 wks vs treatment as usual (TAU) in men on continuous #ADT >6 mos ➡️ mitigates hot flashes/night sweats at 6 wks but not at 6 mos (primary endpt), 14% d/c’ed ADT on TAU arm

#ASCO24 @oncoalert

#DB06 results are here!
T-DXd improves outcomes of endocrine refractory #HER2_low & #HER2_Ultra_Low HR+ #metastatic_breast_cancer

mPFS = 13.2 vs 8.1 mo (delta ~5%) HR 0.6

Impressive ORR = 57% in ITT (62% in #HER2_Ultra_Low )

New SoC!

Given its indication in #HER2_Positive ,

POST-MONARCH, aka confirmation of MAINTAIN. CDK4/6i after CDK4/6i works if the first is palbo and the second is ribo of abema. Full stop. #ASCO24

ONCODOC rand, dbl-blind, placebo-controlled MAST trial low-risk #prostatecancer on AS 1:1 metformin 850 mg BID vs placebo X3 yrs ➡️ no diff in time to path PD or time to tx initiation. Potential harm in BMI>30 at study start & Gleason >8 at PD

#ASCO24 OncoAlert

More strong new data on targeting KRAS G12C but a reminder from Adrian Sacher, M.D. that we still have a lot to learn and need thoughtful studies and biomarker analysis #ASCO24